Ingredient Files and Claims Substantiation: Inside Cosmetics Regulatory Affairs

Introduction

Cosmetics regulatory affairs gets less attention than its pharmaceutical and medical device counterparts, partly because the products themselves carry lower individual risk and partly because, in the United States, cosmetics have historically been regulated more lightly than drugs. That gap has narrowed in recent years, and the role has grown more substantial along with it. A cosmetics regulatory affairs specialist today works across two developed, meaningfully different regulatory systems — US and EU — builds and maintains scientific safety files for every ingredient and finished product, and sits at the boundary between marketing's instinct to make a product sound effective and the legal line that separates a cosmetic claim from a drug claim. It's a role with real technical substance, even though the products on the shelf look nothing like a drug or device.

The Dossier at the Center of the Job: The Safety Substantiation File

Before a cosmetic product reaches market, someone has to build the file that proves, if a regulator or a plaintiff's attorney ever asks, that the product is safe for its intended use. In the US, this takes the form of a safety substantiation file assembled by the responsible person, built from ingredient safety data, any available toxicological information, and increasingly formal risk assessments for ingredients that carry known sensitivities or exposure concerns. In the EU, the equivalent document is far more codified: the Cosmetic Product Safety Report, required under the EU Cosmetics Regulation, which must be prepared and signed off by a qualified safety assessor and follows a prescribed structure covering the product's physicochemical and microbiological characteristics, toxicological profile, and a formal safety assessment conclusion.

Building and maintaining these files is the technical core of the job. It means tracking INCI nomenclature for every ingredient, pulling and organizing supplier safety data, flagging restricted or prohibited substances that differ between US and EU lists, and keeping the file current every time a formulation changes even slightly, since a new fragrance component or preservative system can trigger a fresh safety review.

Where US Law Ends and a Drug Claim Begins

One of the most distinctive parts of this job is the daily negotiation with marketing over what a product is allowed to claim. US law draws a sharp, sometimes counterintuitive line between a cosmetic and a drug based not on the product's ingredients but on its intended use, which is inferred heavily from marketing language. A moisturizer that claims to hydrate skin is a cosmetic. The same moisturizer, marketed as treating eczema or reducing wrinkles through a described biological mechanism, can cross into drug territory and trigger an entirely different, far more burdensome regulatory pathway.

Regulatory affairs professionals in cosmetics spend real time reviewing proposed packaging copy, website language, and influencer talking points against this line, usually well before a product ships, because retroactively walking back a claim that's already in market is far more disruptive than catching it in review. This work also intersects with the Federal Trade Commission, which has its own substantiation standard for advertising claims that's separate from, but related to, FDA's drug-versus-cosmetic distinction. A claim can be technically cosmetic under FDA's framework and still require its own evidence file to satisfy FTC's truth-in-advertising rules.

MoCRA's New Paperwork: Registration, Listing, and Adverse Events

The Modernization of Cosmetics Regulation Act, passed in late 2022, gave FDA meaningfully more authority over cosmetics than it had held for decades, and it reshaped a chunk of this role's day-to-day responsibilities. Facilities that manufacture or process cosmetic products now have to register with FDA, and responsible persons have to submit product listings identifying each product and its ingredients. MoCRA also introduced a formal adverse event reporting requirement, obligating companies to report serious adverse events to FDA within a set window and to maintain records supporting any safety substantiation claims for a defined retention period.

For someone in this role, MoCRA translated into building or updating internal systems: a process for capturing and triaging consumer complaints to determine which rise to the level of a reportable serious adverse event, a facility registration and renewal calendar, and a product listing process that has to stay synchronized with what's actually being manufactured and sold, especially at companies with large, frequently changing product lines.

Working the EU Side: CPSRs and the Responsible Person

Companies selling into the EU need a designated responsible person established within the EU or European Economic Area, who takes on legal accountability for the product's compliance, including ensuring the Cosmetic Product Safety Report exists and is current before the product goes on sale. For regulatory affairs professionals working on both sides of the Atlantic, this means maintaining two parallel safety documentation systems that cover much of the same ground but differ in required structure, in which ingredients are restricted or banned outright, and in how allergens must be disclosed on labeling, since the EU requires specific fragrance allergens to be listed individually above defined concentration thresholds in a way US labeling does not.

Keeping both systems current as formulations evolve, and understanding which changes require updates on one side, the other, or both, is a meaningful part of what separates a cosmetics regulatory affairs specialist who can support a genuinely global brand from one who can only operate domestically.

A Third System: State-Level Rules in the US

Federal MoCRA requirements and EU rules don't cover everything a cosmetics regulatory affairs specialist has to track in practice. California has run its own layer of cosmetics regulation for years, including the California Safe Cosmetics Act, which requires companies to disclose to the state certain ingredients linked to cancer or reproductive toxicity above defined thresholds, and Proposition 65, which requires a warning label on products containing listed chemicals above set exposure levels, regardless of whether those chemicals trigger any federal disclosure requirement. Because California's market is large enough that most national brands sell there, these state rules function as a de facto national requirement for many companies even though they're legally limited to one state.

Retail and distribution partners add a further, non-governmental layer on top of all of this. Major retailers and marketplaces increasingly ask brands to provide safety documentation, restricted substance attestations, or specific ingredient disclosures before they'll list a product, sometimes going beyond what any regulation strictly requires. Keeping track of which retailer asks for what, on top of the federal and state and EU requirements, is a real and growing part of the job, especially for brands trying to scale distribution quickly.

A Typical Week

The work mixes steady documentation with reactive problem-solving. A given week might include reviewing a new formulation's ingredient list against both US and EU restricted substance lists before it goes into development, sitting in on a marketing review to flag a borderline claim before copy is finalized, triaging a handful of consumer complaints to decide whether any meet the bar for a MoCRA adverse event report, and responding to a retailer's request for safety documentation before they'll list a new product. None of it individually looks dramatic, but the cumulative effect of getting it wrong — an unsubstantiated claim, a missed allergen disclosure, an adverse event that should have been reported and wasn't — carries real legal and reputational weight for the company.

How People Get Into This Role

Entry points into cosmetics regulatory affairs are more varied than in pharma or device regulatory affairs, partly because the field is smaller and partly because the scientific background it draws on is broader. People come in from chemistry and formulation science backgrounds, from toxicology, from quality assurance roles at cosmetics or personal care manufacturers, and from regulatory affairs roles in adjacent categories like dietary supplements or OTC drugs, where the claims-substantiation instincts transfer directly even though the specific rules differ. A smaller number come from the legal or compliance side, drawn by the claims-review and labeling-dispute work rather than the ingredient science.

Because MoCRA is still relatively new and EU cosmetics regulation has been tightening its restricted-substance lists steadily, practical familiarity with both frameworks, built through coursework, a prior role, or simply close independent reading of the regulations themselves, stands out on a resume in a field where many candidates only know one side of the Atlantic. Comfort reading and organizing primary source material, rather than relying only on secondhand summaries, tends to separate candidates who can start contributing quickly from those who need months of ramp-up before they can review a formulation or a claim independently.

Conclusion

Cosmetics regulatory affairs doesn't carry the life-or-death stakes of pharmaceutical or device regulation, but it's a genuinely technical role that sits at an unusually interesting intersection of ingredient science, consumer protection law, and marketing judgment. With MoCRA's new federal requirements still settling in and EU cosmetics rules continuing to evolve, companies building global brands need people who can hold both systems in their head at once, and that combination remains harder to find than the relatively quiet profile of this specialty would suggest.